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Objectives: To report on the efficacy and safety of intravitreal aflibercept in patients with 
macular edema secondary to central retinal vein occlusion (CRVO) in an integrated analysis 
of COPERNICUS and GALILEO.
Patients and methods: Patients were randomized to receive intravitreal aflibercept 2 mg 
every 4 weeks or sham injections until week 24. From week 24 to week 52, all intravitreal 
aflibercept-treated patients in both studies and sham-treated patients in COPERNICUS were 
eligible to receive intravitreal aflibercept based on prespecified criteria. In GALILEO, sham-
treated patients continued to receive sham treatment through week 52.
Results: At week 24, mean gain in best-corrected visual acuity and mean reduction in central 
retinal thickness were greater for intravitreal aflibercept-treated patients compared with sham, 
consistent with individual trial results. At week 52, after 6 months of intravitreal aflibercept 
as-needed treatment in COPERNICUS, patients originally randomized to sham group experi-
enced visual and anatomic improvements but did not improve to the extent of those initially 
treated with intravitreal aflibercept, while the sham group in GALILEO did not improve over 
week 24 mean best-corrected visual acuity scores. Ocular serious adverse events occurred 
in ,10% of patients.
Conclusion: This analysis of integrated data from COPERNICUS and GALILEO confirmed 
that intravitreal aflibercept is an effective treatment for macular edema following CRVO.
Keywords: macular edema, central retinal vein occlusion, anti-vascular endothelial growth 
factor, aflibercept, COPERNICUS, GALILEO
Introduction
Retinal vein occlusion is a common cause of vision loss worldwide1 and is the second 
most common retinal vascular disease after diabetic retinopathy.2 The Beaver Dam 
Eye Study found that the prevalence of central retinal vein occlusion (CRVO) was 
0.1% and the 5-year incidence was 0.2%, while the 15-year cumulative incidence of 
CRVO is 0.5%.3,4 Most recently, a pooled analysis of data from .68,000 individuals 
found that 2.5 million adults are affected by CRVO.5 Pharmacologic therapies such as 
intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents and intravitreal 
steroids are shown to be of benefit for eyes with macular edema secondary to CRVO.6 
Due to the side effects associated with steroid use, including increased intraocular 
pressure and cataract, anti-VEGF agents have emerged as first-line therapy for most 
eyes with retinal vein occlusions.
Two anti-VEGF agents are currently approved by the US Food and Drug 
Administration for the treatment of macular edema due to CRVO: ranibizumab and 
aflibercept. Bevacizumab is additionally used for this indication on an off-label basis. 
Aflibercept is a fusion protein of key domains from human VEGF receptors 1 and 2 
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with the constant region (Fc) of human immunoglobulin G 
that binds to multiple VEGF-A isoforms with a high 
affinity.7,8 Intravitreal aflibercept was approved for the 
treatment of macular edema due to CRVO after its efficacy 
and safety were demonstrated in the two Phase III studies, 
COPERNICUS and GALILEO.9–14
Results of the integrated analyses from COPERNICUS 
and GALILEO have not been published. Integrating data 
from both studies increases the number of patients included 
in the treated population, thus increasing the generalizability 
of the results to the global population and minimizing the 
risk of any outlier effect that might be seen in the individual 
studies. Integrating the data also strengthens the ability to 
detect any safety signals and characterizes the safety profile 
of intravitreal aflibercept. Here, we report on the efficacy and 
safety of intravitreal aflibercept at 52 weeks in patients with 
macular edema secondary to CRVO in an integrated analysis 
of data from the COPERNICUS and GALILEO studies. 
Sham-treated patients in the COPERNICUS study were 
eligible to receive intravitreal aflibercept starting at week 24, 
whereas patients in GALILEO continued sham treatment 
through week 52. As treatment schedules and the duration 
of the two studies differed beyond week 52, integrated data 
are shown here only through the week 52 visits.
Patients and methods
Design
COPERNICUS and GALILEO were parallel randomized, 
double-masked Phase III studies comparing intravitreal 
aflibercept with sham for the treatment of macular edema 
secondary to CRVO. The details of these studies have been 
published previously;9–14 key aspects of study design and 
conduct are described here. COPERNICUS was conducted 
at 61 sites in the United States, Canada, Colombia, India, 
and Israel and GALILEO at 63 sites in Asia and Europe. The 
duration of COPERNICUS was 100 weeks and GALILEO 
was 76 weeks. The studies were conducted in compliance 
with ethical guidelines from the Declaration of Helsinki and 
International Conference on Harmonisation and are registered 
on ClinicalTrials.gov as NCT00943072 and NCT01012973, 
respectively. Institutional Review Board/Ethics Committee 
approval was obtained at each site before the start of the studies 
(Supplementary materials). All patients signed a written 
consent form before initiation of study-specific procedures.
Patients
Patients with center-involved macular edema due to CRVO 
for #9 months were included if they were treatment naïve, 
aged $18 years, and had a mean central retinal thickness 
(CRT) $250 µm on optical coherence tomography and 
a best-corrected visual acuity (BCVA) of 73–24 Early 
Treatment Diabetic Retinopathy Study (ETDRS) letters in 
the study eye. Only one eye per patient was included.
Exclusion criteria comprised the following: pregnancy 
or lactation; uncontrolled glaucoma (intraocular pres-
sure $25 mmHg); cataract, vitreoretinal, or filtration surgery; 
bilateral manifestation of retinal vein occlusion; iris neovas-
cularization; any ocular disorder in the study eye that, in the 
opinion of the investigator, may have confounded the inter-
pretation of the study results; or previous treatment with any 
anti-VEGF agents, systemic anti-angiogenic medications, 
or intraocular corticosteroids. Retinal ischemia and afferent 
pupillary defect were not causes for exclusion.
randomization and treatments
Patients were randomized in a 3:2 ratio to receive intravitreal 
aflibercept 2 mg every 4 weeks or sham injections until 
week 24. From week 24 to week 52, all intravitreal 
aflibercept-treated patients in both studies and sham-treated 
patients in COPERNICUS were eligible to receive intrav-
itreal aflibercept based on prespecified retreatment criteria. 
Sham-treated patients in GALILEO were eligible to receive 
intravitreal aflibercept after week 52. Treatment groups are 
shown in Table 1.
The prespecified retreatment criteria included increase 
of .50 µm from lowest previous measurement, new/
persistent cystic retinal changes or subretinal fluid or 
persistent diffuse edema of $250 µm in the central subfield, 
Table 1 Treatment groups
Treatment 
groups
COPERNICUS GALILEO
Baseline to week 20 Week 24 to week 52 Baseline to week 20 Week 24 to week 52
sham sham injection every 
4 weeks
Intravitreal aflibercept 
2.0 mg Prn
sham injection every 
4 weeks
sham injection every 
4 weeks
intravitreal 
aflibercept
Intravitreal aflibercept 
2.0 mg every 4 weeks
Intravitreal aflibercept 
2.0 mg Prn
Intravitreal aflibercept 
2.0 mg every 4 weeks
Intravitreal aflibercept 
2.0 mg Prn
Abbreviation: Prn, pro re nata (as needed).
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loss of $5 ETDRS letters from best previous measurement 
with any increase in CRT, and increase of $5 ETDRS letters 
between current and most recent visit in the absence of retinal 
edema in the central subfield. Patients who did not meet 
any of the retreatment criteria were given sham injections 
to maintain masking. In case of neovascular complications 
(eg, neovascularization of the anterior segment, at the optic 
disk, or elsewhere in the fundus), patients were eligible for 
treatment with panretinal photocoagulation.
Outcomes
The primary end point was the proportion of eyes that 
gained $15 letters in BCVA at week 24. Herein, results are 
presented for the integrated COPERNICUS and GALILEO 
studies. Results from baseline to week 24 are presented for 
two groups of patients: the intravitreal aflibercept group 
(n=217) and the sham group (n=141). Results from week 24 
to week 52 are presented for three groups of patients: the 
intravitreal aflibercept group (n=217), the sham → intra-
vitreal aflibercept group (ie, patients in COPERNICUS 
originally randomized to sham injections who crossed over 
to active treatment after week 24; n=73), and the sham group 
(ie, patients in GALILEO originally randomized to sham 
injections who had not crossed over to active treatment by 
week 52; n=68).
statistics
All safety and efficacy variables were analyzed descriptively 
with appropriate statistical methods: categorical variables 
by frequency tables (absolute and relative frequencies) and 
continuous variables by sample statistics (ie, mean, standard 
deviation). Patients included in the evaluations are those from 
the full analysis set, which includes all randomized subjects 
who received any study medication and had at least one 
baseline and one post-baseline assessment. The full analysis 
set was analyzed as randomized. For missing efficacy data 
after start of treatment, the last observation carried forward 
(LOCF) approach was applied. Safety analysis included all 
patients who received any study treatment.
Results
When data from the two studies were integrated, baseline 
demographic and disease characteristics were similar across 
the two treatment groups (Table 2). Mean age at baseline was 
62.9 years in the intravitreal aflibercept group and 65.7 years 
in the sham group. Mean baseline BCVA was 52.0 letters in 
the intravitreal aflibercept group and 49.9 letters in the sham 
group. The majority of patients in both treatment groups 
had perfused retinas (classified as ,10 disk areas of retinal 
capillary non-perfusion on fluorescein angiography) at 
baseline (76.5% of patients in the intravitreal aflibercept 
group and 73.8% in the sham group). There were fewer 
patients with perfused retinas at baseline in COPERNICUS 
than GALILEO (67.9% versus 83.6%).
From baseline to week 24, the mean (standard deviation) 
number of injections received in the intravitreal aflibercept 
group was 5.8 (0.8). Among patients who completed at least 
through week 24, the mean (standard deviation) number of 
active injections received from week 24 to week 52 was 
2.6 (1.7) in the intravitreal aflibercept group, 3.9 (2.0) in 
Table 2 Baseline demographic and disease characteristics (full analysis set)
COPERNICUS 
(n=187)
GALILEO 
(n=171)
Integrated
Intravitreal aflibercept 
group (n=217)
Sham group 
(n=141)
Mean (sD) age, years 66.3 (13.9) 61.5 (12.9) 62.9 (13.3) 65.7 (13.9)
sex, female, n (%) 80 (43.0) 76 (44.4) 127 (58.5) 66 (46.8)
Mean (sD) BCVa, eTDrs letters 50 (14.1) 52.2 (15.7) 52.0 (14.9) 49.9 (14.9)
Mean (sD) CrT, µm 665.8 (239.8) 665.5 (231.0) 672.0 (235.7) 655.7 (235.1)
Mean (sD) time since CrVO diagnosis, months 2.4 (2.8) n/aa 2.7 (3.0) 2.4 (2.5)
Perfusion status, n (%)
Perfused 127 (67.9) 143 (83.6) 166 (76.5) 104 (73.8)
non-perfused 29 (15.5) 14 (8.2) 24 (11.1) 19 (13.5)
indeterminate 31 (16.6) 14 (8.2) 27 (12.4) 18 (12.8)
Retinal fluid, n (%)
absent 3 (1.6) 2 (1.2) 4 (1.8) 1 (0.7)
Present 182 (97.9) 168 (98.2) 211 (97.2) 139 (99.3)
Undetermined 1 (0.5) 1 (0.6) 2 (1.0) 0
Note: aFor galileO, time since diagnosis reported in days: mean (sD) = 81.8 (85.4).
Abbreviations: BCVa, best-corrected visual acuity; CrT, central retinal thickness; CrVO, central retinal vein occlusion; eTDrs, early Treatment Diabetic retinopathy study; 
n/a, not available; sD, standard deviation.
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the sham → intravitreal aflibercept group, and 0 (0) in the 
sham group.
At week 24, the proportion of patients who 
gained $15 letters from baseline was 60.4% in the intra-
vitreal aflibercept group and 17.0% in the sham group. At 
week 52, the proportion of patients who gained $15 letters 
from baseline was 58.5% in the intravitreal aflibercept 
group, 30.1% in the sham → intravitreal aflibercept group 
(COPERNICUS), and 32.4% in the sham group (GALILEO). 
Between week 24 and week 52, the proportion of patients 
who gained $15 letters from baseline increased by 
17.8 percentage points in the sham → intravitreal aflibercept 
group and by 10.3 percentage points in the sham group.
At week 24, the mean change in BCVA from base-
line was +17.7 letters in the intravitreal aflibercept group 
and -0.5 letters in the sham group (Figure 1). At week 52, 
the mean change in BCVA from baseline was +16.5 letters in 
the intravitreal aflibercept group, +3.8 letters in the sham → 
intravitreal aflibercept group, and +3.8 letters in the sham 
group (Figure 2). Between week 24 and week 52, the mean 
change from baseline in BCVA increased by 7.8 letters in 
the sham → intravitreal aflibercept group, and by 0.5 letters 
in the sham group.
At week 24, the mean change in CRT from base-
line was -453.1 µm in the intravitreal aflibercept group 
and -157.2 µm in the sham group (Figure 3). At week 52, 
the mean change in CRT from baseline was -418.0 µm in 
the intravitreal aflibercept group, -381.8 µm in the sham → 
intravitreal aflibercept group, and -219.3 µm in the sham 
group (Figure 4).
At week 52, ocular serious adverse events occurred 
in 16 (7.3%), 12 (16.2%), and six (8.8%) patients in the 
intravitreal aflibercept group, the sham → intravitreal 
aflibercept group, and the sham group, respectively 
(Table 3). Two Antiplatelet Trialists Collaboration-defined 
arterial thromboembolic events (APTC-ATEs) occurred 
overall. One patient in the intravitreal aflibercept group 
experienced a non-fatal myocardial infarction and one 
patient in the sham → intravitreal aflibercept group expe-
rienced vascular death. There were no APTC-ATEs in the 
sham group (Table 4).
Discussion
The aim of this article is to report the efficacy and safety 
of intravitreal aflibercept in patients with macular edema 
due to CRVO in an integrated analysis of data from the 
COPERNICUS and GALILEO studies. The integrated data 
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Figure 2 Mean change in BCVa from baseline to week 24–week 52 (lOCF).
Abbreviations: BCVa, best-corrected visual acuity; eTDrs, early Treatment 
Diabetic retinopathy study; lOCF, last observation carried forward.
    (7'
56
OHWWH
UV
±
±





±


:HHN
&23(51,&86LQWUDYLWUHDODIOLEHUFHSWQ &23(51,&86VKDPQ *$/,/(2LQWUDYLWUHDODIOLEHUFHSWQ *$/,/(2VKDPQ 
$
(7'
56
OHWWH
UV
±
±





      ±

:HHN
,QWUDYLWUHDODIOLEHUFHSWQ 6KDPQ 
%
Figure 1 Mean change in BCVa for (A) COPerniCUs and galileO and (B) integrated data set from baseline to week 24 (lOCF).
Abbreviations: BCVa, best-corrected visual acuity; eTDrs, early Treatment Diabetic retinopathy study; lOCF, last observation carried forward.
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of the COPERNICUS and GALILEO studies confirm the 
findings of the individual studies.
Both the COPERNICUS and GALILEO studies docu-
mented the beneficial treatment effect of intravitreal afliber-
cept compared with sham injections; however, there were 
differences between the studies that should be considered. 
The natural history (sham-treated) groups demonstrate that 
the patients enrolled in the two studies were slightly different 
in some aspects, likely due in part to the different countries 
and geographic regions where they were conducted. Specifi-
cally, visual gains among patients originally randomized to 
sham treatment were generally lower in COPERNICUS than 
those in GALILEO, both before and after initiation of treat-
ment with intravitreal aflibercept at week 24. This finding 
may be due to the larger number of patients with non-perfused 
retinas at baseline in COPERNICUS compared with 
GALILEO10,13 or to some other unidentified factor(s).
The data from the sham → intravitreal aflibercept group 
in COPERNICUS support that a 6-month delay in initiating 
treatment with intravitreal aflibercept can result in diminished 
visual and morphologic gains, and after 12 months without 
treatment, as observed in GALILEO, sham treatment did 
not show additional visual improvements beyond the small 
gains seen at week 24. At week 24, after receiving 6-monthly 
injections of intravitreal aflibercept, patients in the intravitreal 
aflibercept group experienced greater visual gains compared 
with patients who received sham treatment (+17.7 letters 
versus -0.5 letters for the sham group). From week 24 to 
week 52, visual acuity gains were maintained in the intra-
vitreal aflibercept group. The visual outcomes at week 52 
in the sham group of COPERNICUS that crossed over to 
receive intravitreal aflibercept at week 24 did not reach the 
level of those attained by patients who received intervention 
with intravitreal aflibercept at the start of the study, despite 
a marked improvement in anatomy. Furthermore, patients 
in the GALILEO study who did not cross over to treatment 
with intravitreal aflibercept until week 52 also did not show 
any meaningful visual gains. These data suggest that a delay 
in treatment initiation with intravitreal aflibercept may result 
in less optimal visual outcomes.
Integrated morphologic results at week 24 followed 
the same pattern as the visual results. At week 24, the 
improvements in CRT from baseline were greater in the 
intravitreal aflibercept group than in the sham group (-453.1 
versus -157.2 µm), and these improvements were maintained 
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Figure 3 Mean change in CrT for (A) COPerniCUs and galileO and (B) integrated data set from baseline to week 24 (lOCF).
Abbreviations: CrT, central retinal thickness; lOCF, last observation carried forward.
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in the intravitreal aflibercept group through week 52. 
Although CRT improvements were substantial in the sham → 
intravitreal aflibercept group, anatomic improvements were 
not mirrored by similar improvements in visual acuity, con-
firming the importance of early intervention in eyes with 
macular edema due to CRVO. It should be noted that LOCF 
data generally leave a gap between patients treated from base-
line and patients receiving rescue later on due to dropouts, 
resulting in an underestimation of the effect of crossover.
The benefits of early treatment have been seen in other 
studies of patients with CRVO. Analyses of eyes treated with 
dexamethasone intravitreal implant15 and with ranibizumab16 
in the Phase III trials of these drugs have demonstrated that 
although the macula can be dried effectively even after a 
delay in treatment, visual improvements do not catch up to 
those achieved in earlier-treated eyes.
The results of this integrated analysis of COPERNICUS 
and GALILEO are consistent with the safety profile of 
intravitreal aflibercept. The ocular serious adverse events 
observed in this study largely comprised adverse events 
attributable to the underlying disease.
Conclusion
Based on the integrated data from the COPERNICUS and 
GALILEO studies, intravitreal aflibercept is a well-tolerated 
and effective treatment for macular edema secondary to 
CRVO. The integrated data show that macular edema 
secondary to CRVO can be managed successfully with initial 
monthly intravitreal aflibercept injections, consistent with 
results shown in the respective trials.10,12 Delay in treatment 
initiation with intravitreal aflibercept in the COPERNICUS 
study resulted in limited gains in visual acuity by week 52. 
The integrated results of these studies reinforce the robust-
ness of the treatment effect of intravitreal aflibercept in 
retinal vein occlusions to maximize visual and morphologic 
benefits.
Table 3 Ocular saes from baseline to week 52 by MedDra Preferred Term (safety analysis set)
Intravitreal aflibercept 
group (n=218)
Sham → intravitreal 
aflibercept group (n=74)
Sham group 
(n=68)
All patients 
(n=360)
Patients with $1 sae in 
the study eye, n (%)
16 (7.3) 12 (16.2) 6 (8.8) 34 (9.4)
Cataract 1 (0.5) 1 (1.4) 0 2 (0.6)
Corneal abrasion 1 (0.5) 0 0 1 (0.3)
Cystoid macular edema 1 (0.5) 0 0 1 (0.3)
endophthalmitis 1 (0.5) 0 0 1 (0.3)
glaucoma 0 3 (4.1) 2 (2.9) 5 (1.4)
iris neovascularization 1 (0.5) 2 (2.7) 0 3 (0.8)
Macular fibrosis 1 (0.5) 0 0 1 (0.3)
Macular ischemia 1 (0.5) 0 0 1 (0.3)
Macular edema 4 (1.8) 0 2 (2.9) 6 (1.7)
retinal artery occlusion 1 (0.5) 0 0 1 (0.3)
retinal hemorrhage 0 2 (2.7) 0 2 (0.6)
retinal tear 0 2 (2.7) 0 2 (0.6)
retinal vein occlusion 2 (0.9) 1 (1.4) 0 3 (0.8)
Visual acuity reduced 1 (0.5) 1 (1.4) 1 (1.5) 3 (0.8)
Vitreous detachment 1 (0.5) 0 0 1 (0.3)
Vitreous hemorrhage 2 (0.9) 5 (6.8) 1 (1.5) 8 (7.8)
Abbreviation: sae, serious adverse event.
Table 4 aPTC-aTes from baseline to week 52 (safety analysis set)
Intravitreal aflibercept 
group (n=218)
Sham → intravitreal 
aflibercept group (n=74)
Sham group 
(n=68)
All patients 
(n=360)
Patients with any aPTC-aTe, n (%) 1 (0.5) 1 (1.4) 0 2 (0.6)
non-fatal myocardial infarction 1 (0.5) 0 0 1 (0.3)
non-fatal stroke 0 0 0 0
Vascular death 0 1 (1.4) 0 1 (0.3)
Abbreviation: APTC-ATEs, Antiplatelet Trialists Collaboration-defined arterial thromboembolic events.
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Supplementary material
list of institutional review Boards and 
ethic Committees for COPerniCUs and 
galileO sites
COPerniCUs
USA: Copernicus Group IRB, UCSD Human Research 
Protection Program, Cleveland Clinic IRB, IRB, OPRS; 
Canada: The University of British Columbia Office of Research 
Services Clinical Research Ethics Board, IRB Services, 
Capital District Health Authority Research Ethics Board, 
University of Western Ontario Health Sciences Research 
Ethics Board, Research Ethics Research and Development 
Vancouver Island Health Authority, Sunnybrook Research 
Ethics Board; India: Regional Institute of Ophthalmology; 
Ethics Committee Hyderabad Eye Research Foundation, 
Narayana Nethralaya Institutional Ethics Committee; Israel: 
Helsinki Committee of Tel Aviv, Helsinki Committee of 
Rabin Medical Center, Helsinki Committee of Kaplan 
Medical Center, Helsinki Committee of Meir Medical 
Center; Colombia: Instituto Nacional de Investigacion en 
Oftalmologia – INIO, Comite de etica en Investigacion de 
Fundacion Oftalmological Nacional – FUNDONAL.
galileO
Australia: Bellberry Human Research Ethics Committee, 
Royal Prince Alfred Hospital, The Royal Victorian Eye & 
Ear Hospital; Austria: Ethikkommission der Medizinischen 
Universität Wien und des AKH, Ethikkommission des Landes 
Oberösterreich, Ethikkommission des KH Barmherzige Brüder 
Linz; France: Comite de Protection des Personnes sud ouest et 
Outremer III; Germany: Ethikkommission an der Medizinis-
chen Fakultät Rheinische Friedrich-Wilhelms-Universität 
Bonn, Bereich Humanmed. d. Georg-August-Universität 
Göttingen Medizinische Fakultät Ethik-Kommission, 
Ethik-Kommission bei der Ärztekammer des Saarlandes, 
Ethik-Kommission bei der Ärztekammer Hamburg, 
Ethik-Kommission bei der Landesärztekammer Hessen, 
Ethikkommission der Ärztekammer Westfalen-Lippe, Ethik-
Kommission der Landesärztekammer Rheinland-Pfalz, Ethik-
Kommission der Sächssischen Landesärztekammer, Klinikum 
der Christian-Albrechts-Universität Ethik-Kommission, 
Ethik-Kommision der Medizinischen Fakultät der Eberhard-
Karls-Universität und am Universitätsklinikum Tübingen, 
Ethikkommission des Fachbereichs Humanmedizin, Klinikum 
rechts der Isar Fakultät für Medizin Ethik-Kommission, 
Ethikkommission an der Medizinischen Fakultät Rheinische 
Friedrich-Wilhelms-Universität Bonn, Ethik-Kommission 
der Technischen Universität Dresden, Ethik-Kommission 
der Medizinischen Fakultät der Universität zu Köln, 
Ethik-Kommission der Medizinischen Fakultät der Universität 
Leipzig, Universitätsklinik Gießen und Marburg GmbH 
Standort Marburg Ethik Kommission, Universitätsklinikum 
Aachen Ethik-Kommission an der Medizinischen Fakultät, 
Ethik-Kommission der Medizinischen Fakultät der 
Universität Duisburg-Essen, Universitätsklinikum Freiburg 
Ethik-Kommission, Ethikkommission der Med. Fakultät 
Heidelberg, Universitätsklinikum Regensburg Ethikkom-
mission der medizinischen Fakultät, Universitätsklinikum 
Schleswig-Holstein/AÖR Ethikkommission; Hungary: ETT 
Klinikai Farmakológiai Etikai Bizottság, ETT Klinikai 
Farmakológiai Etikai Bizottság; Italy: Comitato etico per la 
sperimentazione clinica dei medicinali dell’ A.O.U. Careggi, 
Comitato Etico A.O.U. Ospedali Riuniti Umberto I-Lancisi-
Salesi, Comitato Etico A.O.U. Policlinico Consorziale di Bari, 
Comitato Bioetico dell´Azienda Ospedaliero-Universitaria 
Policlinico di Catania, Comitato Etico Indipendente Presso 
la Fondazione PTV Policlinico Tor Vergata, Comitato Etico 
della ASL RM/A di Roma, Comitato Etico ASL TO/2 di 
Torino, Comitato Etico IRCCS Fondazione S.Raffaele del 
Monte Tabor di Milano, Comitato di Etica Fondazione 
Irccs Ca’Granda Ospedale Maggiore Policlinico; Japan: 
Juntendo University Urayasu Hospital IRB, Kyoto University 
Hospital IRB, Nagoya City University Hospital IRB, Nagoya 
University Hospital IRB, Osaka University Hospital IRB, 
Surugadai Nihon University Hospital IRB; South Korea: 
Asan Medical Center, Gachon University Gil Medical Center, 
Seoul National University Bundang Hospital IRB, Seoul 
National University Hospital IRB, Severance Hospital 
Institutional Review Board, St Mary Hospital IRB; Latvia: 
Ethics Committee for Clinical Trials; Singapore: NHG 
Domain Specific Review Boards (DSRB), Singhealth 
Centralised Institutional Review Board.
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